Pediatric Ewing sarcoma is characterized by the expression of chimeric fusions of EWS and ETS family transcription factors, representing a paradigm for studying cancers driven by transcription factor rearrangements. In this study, we describe the somatic landscape of pediatric Ewing sarcoma. These tumors are among the most genetically normal cancers characterized to date, with only EWS -ETS rearrangements identifi ed in the majority of tumors . STAG2 loss, however, is present in more than 15% of Ewing sarcoma tumors; occurs by point mutation, rearrangement, and likely nongenetic mechanisms; and is associated with disease dissemination. Perhaps the most striking fi nding is the paucity of mutations in immediately targetable signal transduction pathways, highlighting the need for new therapeutic approaches to target EWS -ETS fusions in this disease.
INTRODUCTION
The sequencing of cancer genomes in aggressive pediatric solid tumors, such as rhabdoid tumors and retinoblastoma, has revealed remarkably stable genomes ( 1, 2 ) . In both cases, oncogenesis is thought, at least in part, to be driven by epigenetic deregulation. It has been hypothesized that pediatric solid tumors notable for recurrent translocations involving transcription factors will also have relatively stable genomes, as has already been observed in acute myeloid leukemia and rhabdomyosarcoma with recurrent cytogenetic translocations ( 3, 4 ) . Studies to systematically address this hypothesis are just beginning to emerge. Ewing sarcoma is an aggressive, poorly differentiated tumor, typically arising from bone, and is characterized by highly recurrent translocations involving ETS transcription factors, with EWS -FLI and EWS -ERG translocations being the most common ( 5, 6 ) . Ewing sarcoma cells have a strict dependency on EWS-ETS fusion proteins, supporting the notion that these translocations are a critical oncogenic event in this disease ( 7 ) . Although the EWS -FLI rearrangement was described over 20 years ago, effective therapy directly targeting this transcription factor abnormality has yet to be developed. New therapeutic strategies for this disease are needed because the vast majority of children with metastatic or relapsed Ewing sarcoma will die despite intensive, multimodality therapy ( 8, 9 ) . Moreover, even for children who are cured, the long-term morbidity of cytotoxic treatment is signifi cant ( 10 ) .
Efforts to discover collaborating, and potentially targetable, genetic alterations in Ewing sarcoma tumors have primarily focused on the study of copy-number alterations, with several studies reporting copy-number gains of chromosome 8 in nearly 50% of tumors ( 11 ) . However, with the exception of focal deletions at the CDKN2A locus on 9p21, specifi c genes of relevance have yet to be elucidated from these studies ( 12, 13 ) . Furthermore, few recurrent somatic mutations have been reported in Ewing sarcoma, with the notable exceptions of TP53 (5%-20%) and more recently the cohesin complex family member STAG2 (20%), with neither of these imminently druggable (13) (14) (15) (16) . We sought to defi ne the genomic landscape of pediatric Ewing sarcoma by integrating multiple next-generation sequencing methods applied to a large panel of human Ewing sarcoma tumors.
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tumors from 66 patients, and 11 cell lines. We also performed whole-genome sequencing (WGS), genotyping array (SNP array), and transcriptome sequencing (RNASeq) on a subset of these samples ( Fig. 1A ; Supplementary Fig. S1 ; Supplementary Table S1A-S1D) . We found only 12 genes with nonsilent mutations in more than one sample of the 26 tumors with normal controls and found that EWS -ETS translocations were the only recurrent rearrangements identifi ed from WGS and RNASeq (Supplementary Tables S2A-S2D, S3 , and S4A-S4D). Although all recurrent mutations were detected in WES, only fi ve of these genes ( ERF , BCORL1 , and TP53 were mutated in 2 of 26 tumors and MLL2 and STAG2 in 3 of 26 tumors) had mutations that were confi rmed in a complementary sequencing approach (WGS or RNASeq) and were predicted to be expressed by RNASeq ( Fig. 1A ; Supplementary Table S3 ; Supplementary Fig. S2 ). We also identifi ed 10 genes with mutation sites listed in the Catalogue of Somatic Mutations in Cancer (COSMIC; v51), but of these only TP53 was mutated in more than one sample (Supplementary Table  S2A -S2D; ref. 18 ). We used the MutSig 2CV algorithm to detect signifi cantly mutated genes from 26 tumors with normal pairs and found that only STAG2 was signifi cantly mutated (Supplementary Table S5 ; ref. 19 ) . With an overall mutation rate of 0.62 mutations per megabase (Mb), this analysis had 90% power to detect signifi cantly mutated genes present in 30% or more of patients (Supplementary Fig. S3 ; Supplementary Table S6A; ref. 19 ) .
To increase our power to detect less commonly mutated genes, we developed an approach to analyze WES for Ewing sarcoma tumors for which normal pairs were unavailable. This allowed us to extend our discovery set from 26 to 92 tumors. Standard alignment and analysis of WES data from 66 tumors without normal pairs yielded an average of 521 variants per Mb. Recognizing that these variants are composed of germline events and artifacts, in addition to somatic mutations, we fi ltered these data against common germline variants in the 1000 Genome Project and Exome Sequencing Project (ESP) as well as a panel of more than 2,900 normal exomes to remove germline events and recurrent artifacts, which reduced this rate to 6.1 variants/Mb (Supplementary  Tables S6B and S7 ; refs. 20, 21 ) . After combining these results with the 26 tumor-normal pairs (also now fi ltered by the panel of normal samples), the entire cohort had an average variant rate of 4.6/Mb. This improved our sensitivity to detect signifi cantly mutated genes (90% power) present in 15% or more of patients (Supplementary Fig. S3 ; ref. 19 ) . We hypothesized that the remaining rare germline events would be widely distributed across the exomes, allowing MutSig to detect signifi cant somatic events. Variants were analyzed with the MutSig 2CV algorithm, and consistent with the above hypothesis, only four signifi cantly mutated genes were identifi ed (Supplementary Table S8 ). STAG2 and TP53 were the only two genes known to be cancer-associated. RPTN , a member of the epidermal differentiation complex, and PRB2 , a member of the human salivary proline-rich protein family, were also signifi cantly mutated on the basis of this analysis ( 22, 23 ) . Neither of these genes, however, was expressed in any of the Ewing sarcoma tumors or cell lines based on the RNASeq data, suggesting that these variants are unlikely to be driver events in Ewing sarcoma. These results confi rm that there are few signifi cantly mutated genes in Ewing sarcoma other than EWS -ETS rearrangements at frequencies greater than 15%.
We also noted a stark paucity of mutations in genes involved in signaling pathways. In fact, of the 26 tumornormal pairs, EPHA7 was the only tyrosine kinase recurrently mutated, and there was only 1 patient (SJDES001-R) with a candidate targetable lesion ( PTEN mutation coupled with deletion of the other allele). Furthermore, there was no enrichment of mutated genes in gene signatures defi ned by tyrosine kinase activity or pathways reported to be active in Ewing sarcoma (i.e., GLI1, MAPK, and PI3K-AKT-mTOR pathways) when considering either the 26 tumors with normal pairs or the entire collection of 92 tumors (Supplementary Table S9 ; refs. [24] [25] [26] [27] [28] [29] [30] [31] [32] . Given the lack of highly recurrent mutations, it is also notable that there was no enrichment of mutations in chromatin-modifying genes.
Finally, somatic copy-number alterations (SCNA) were identifi ed from SNP-array data and by read-depth analysis of WES data. GISTIC2.0 analysis identifi ed signifi cant copynumber gains of chromosome 8 in 45% (41 of 92) of cases and focal deletions at 9p21.3 in 28% of tumors (5 of 18 by SNP array and 22% or 20 of 92 by SNP array plus WES), consistent with loss of CDKN2A ( Fig. 1A-C ; Supplementary Fig.  S4A ; Supplementary Table S10; ref. 33 ) . No signifi cant focal amplifi cations were found. One recent study reported recurrent focal deletions of SMARCB1 and RELN in Ewing sarcoma tumors, but we were unable to identify these aberrancies by SNP array or WES in our cohort ( 34 ) . As pointed out by the authors of this previously published study, these deletions may be more prevalent in Ewing sarcoma tumors with either atypical features or mixed features of both Ewing sarcoma and rhabdoid.
Signifi cantly Mutated Genes in Ewing Sarcoma
Mutations in TP53 have been reported in 3% to 14% of Ewing sarcoma tumors ( 13, 14 ) . We found nonsilent coding aberrancies of TP53 in 6% [6 of 96 samples including the Fig. S4B and S4C) . None of the 51 tumors acquired at the time of patient diagnosis had a TP53 mutation, whereas 25% of tumors acquired after treatment (3 of 12; 95% CI, 6%-57%) were mutated at TP53 ( P = 0.006 by Fisher exact test). Furthermore, relapses from two different time points from a single patient (SJDES007-R1 and SJDES007-R2) acquired unique TP53 mutations (p.C176F and p.C135F, respectively). Along with the striking observation that Ewing sarcoma is rarely diagnosed in families with Li-Fraumeni syndrome, these data support the hypothesis that TP53 mutations play a greater role in treatment resistance 
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or disease recurrence than in the initiation of Ewing sarcoma, as previously suggested in the literature ( 13 ) .
Mutations in STAG2 were recently identifi ed in several types of cancer, including Ewing sarcoma ( 4 , 15 , 16 , 35-37 ) . We identifi ed eight nonsilent single-nucleotide variants (SNV) or indels in STAG2 in 96 tumors, including two distinct STAG2 mutations in separate relapses from the same patient (SJDES007-R1 and SJDES007-R2), as well as a previously unreported STAG2 -MAP7D3 fusion in a Ewing sarcoma cell line ( Fig. 1A In recent studies, there have been confl icting reports about the association of STAG2 loss with increased aneuploidy in cancer ( 15 , 35 , 36 , 38 ) . We found that tumors with loss of STAG2 expression had a slightly higher mean proportion of the genome with SCNAs (0.15 for STAG2 positive vs. 0.36 for STAG2 loss; P = 0.009 by Mann-Whitney test) but no difference in ploidy ( Fig. 2D and E ) . However, we also noted that some STAG2 mutations were identifi ed in tumors with TP53 mutations and/or from patients who had previously received treatment, factors known to induce chromosomal instability. In fact, we found that TP53 mutations occurred signifi cantly more often than expected in samples with aberrant STAG2, as determined by IHC or by the identifi cation of a mutation when IHC was unavailable ( P = 0.014 by Fisher exact test). When limiting our analysis to tumors that are TP53 wildtype and obtained at diagnosis, we found that there was no signifi cant difference in the rate of SCNAs in tumors with or without loss of STAG2 expression (0.14 for STAG2 positive vs. 0.27 for STAG2 loss; P = 0.108 by Mann-Whitney test; Fig. 2F ). Furthermore, we did not observe any copy-number changes in one tumor sample with a clonal STAG2 mutation (SJDES006; Supplementary Fig. S4A ). Rather, we observed that 88% of patients (7 out of 8; 95% CI, 47%-100%) with STAG2 loss at the time of diagnosis also presented with clinical evidence of metastatic disease compared with only 27% (14 of 51; 95% CI, 16%-42%) of those whose diagnostic tumor sample expressed STAG2 ( P = 0.002 by Fisher exact test), demonstrating that STAG2 loss is associated with disease dissemination in Ewing sarcoma ( Fig. 2G ) . Furthermore, we also performed single-sample gene set enrichment analysis (ssGSEA) to identify gene signatures that were enriched in samples with STAG2 loss versus STAG2 expression. Because of the small number of tumors with both loss of STAG2 expression and available RNASeq data, we combined RNASeq data from tumors and cell lines for this analysis. Two of the 11 signatures that are enriched in samples with loss of STAG2 expression were gene sets associated with metastasis in cancer ( 
Alterations in ETS Transcription Factors
We identifi ed EWS -ETS rearrangements for all samples with WGS and EWS -ETS fusion transcripts in all samples with RNASeq data (Supplementary Table S4A-S4C) . Reciprocal ETS -EWS fusion transcripts were detected in only four samples, each with fi ve or fewer reads. In some cases, RNASeq detected multiple EWS -ETS fusions, a phenomenon previously reported in Ewing sarcoma (39) (40) (41) . In all samples, at least one fusion variant was expected to result in the translation of the ETS portion of the chimeric protein in-frame. These in-frame variants were always found to have higher expression than outof-frame variants in these samples, reaffi rming that alternative splicing is an effective mechanism for expressing EWS-ETS fusion proteins for rearrangements otherwise predicted to yield out-of-frame and truncated fusion forms ( P < 0.0001 by Mann-Whitney test; Supplementary Table S4C ). We also found that wild-type FLI and ERG exons were poorly expressed in EWS -ETS -expressing tumors ( Fig. 3A -C and Supplementary Table S14A and S14B). These data indicate that EWS -ETS rearrangements are necessary for the expression of FLI and ERG and that alternative splicing of EWS -ETS rearrangements is sometimes necessary for the in-frame translation of these ETS transcription factors in Ewing sarcoma.
Recent work in prostate cancer demonstrated that nonrearranged ETS transcription factor aberrancies play a role in the development of disease even in tumors expressing ETS fusions and that ETS2 repressor factor ( ERF ) expression has also been reported to attenuate ETS -associated tumorigenesis ( 42, 43 ) . Therefore, we looked for evidence of other ETS aberrancies in our samples. Although mutations in ETS family genes were not statistically enriched among the 92 tumors sequenced by GSEA, we identifi ed three samples with nonsilent coding variants in ERF (3%; 3 of 92; 95% CI, 1%-9%), leading to a relative decrement in the expression of the ERF transcript for the only patient with RNASeq data and an ERF mutation, SJDES012 [reads per kilobase per million (RPKM) = 20.7, wild-type ERF RPKM; range, 23.3-57.6; Supplementary Table S11A-S11D]. We also identifi ed recurrent, focal deletions of the ETS1 gene (11%; 10 out of 92; 95% CI, 5%-19%), originating at the FLI breakpoint, in Ewing sarcoma tumors. None of these samples, however, had RNA available for determining the effect of deletion on ETS1 expression, and we did not identify point mutations in this gene (Supplementary Fig. S5 and Supplementary Table S15).
Ewing Sarcoma Genomics after Treatment and in Established Cell Lines
Of the 26 tumors with available normal controls, 16 patients were sampled at diagnosis and eight sampled after treatment. For this cohort, upfront treatment used the same chemotherapy agents for all patients except one (Supplementary Table S1A-S1D). Diagnostic and treated tumors differed signifi cantly in their mutation rates (0.37 vs. 1.11 mutations per Mb, respectively; P = 0.0017 by Mann-Whitney test; Fig. 4A and B ; Supplementary Table S6A) . SNVs were predominantly C to T transitions with the majority subcategorized as *CpG to T mutations, a common pattern attributed to spontaneous deamination of 5-methyl-cytosine and associated with cancers with high levels of methylation ( 44, 45 ) . In treated tumors, there was a relative increase in substitutions of cytosine at TpC Table S13 . I and J, GSEA plots of running enrichment scores for two metastatic signatures (j and k) signifi cantly enriched in STAG2 loss samples. **, P < 0.01. A673  EW8  TC32  TC71  EWS502  EWS834  RDES  SKNEP1  CADO-ES1  TTC466   STAG2 
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dinucleotides, a pattern attributed to the activity of APOBEC enzymes in regions of DNA damage. However, there was no evidence of kataegis or increase in APOBEC expression in treated samples, patterns usually associated with APOBEC-induced mutations ( Fig. 4C and D ; refs. [44] [45] [46] [47] . Although the analysis of translocations was limited by the relative paucity of WGS samples, there was a trend toward an increased number of rearrangements in treated samples compared with diagnostic samples, but there was no evidence of chromothripsis ( P = 0.057 by Mann-Whitney test; Fig. 4E Fig. S6A and S6B ). We also found that copy-number gains of chromosome 1q were signifi cantly more common in treated samples (50%; 4 of 8; 95% CI, 16%-84%) than in diagnostic samples (14%; 7 of 51; 95% CI, 6%-26%; P = 0.03 by Fisher exact test). In aggregate, both sequencing and copy-number data demonstrate that anti-Ewing treatment regimens are associated with an increase in somatic aberrancies in Ewing sarcoma tumors.
To determine whether well-established Ewing sarcoma cell lines have retained features of Ewing sarcoma tumors, we analyzed WES, SNP-array, RNASeq, IHC, and Western blot analysis data from 11 cell lines (Supplementary Table S1C ). Because paired normal controls for cell lines are unavailable, WES data were subjected to the same fi ltering process as tumors for which we did not have matched normal samples (Supplementary Table S16 ). We detected an EWS -ETS fusion for all cell lines with RNASeq data (Supplementary Table S4C ). We found a signifi cantly increased rate of STAG2 mutations (36%; 4 of 11; 95% CI, 11%-69%; P = 0.016), STAG2 loss by Western blot analysis or IHC (70%; 7 of 10; 95% CI, 35%-93%; P = 0.0006), TP53 mutations (64%; 7 of 11; 95% CI, 31%-89%; P < 0.0001), CDKN2A deletion (55%; 6 of 11; 95% CI, 23%-83%; P = 0.028), and chromosome 1q copy-number gain (55%; 6 of 11; 95% CI, 23%-83%; P = 0.011) in cell lines compared with tumor samples by the Fisher exact test. There was no significant difference in the rate of copy-number gains of chromosome 8 (6 of 11), and although there were more cell lines from females (8 of 11) than from males, this did not reach statistical signifi cance when compared with the gender of patients in our study ( Fig. 5A ) . We also performed principal component analysis using the RNASeq data from all tumors and cell lines. Projection of the fi rst two principal components, accounting for the largest amount of variance in the samples, revealed that cell lines and tumors clustered separately ( Fig. 5B ) . However, only the fi rst principal component (PC1) was found to signifi cantly discriminate tumors and cell lines ( P < 1 × 10 −14 Reads generated from the wild-type allele or translocated allele cannot be distinguished. Prefusion EWS RPKMs (blue) are generated from all reads that map to the exons before the site of the EWS -ETS breakpoint (reads from rearranged and wild-type alleles cannot be distinguished). Postfusion EWS RPKMs (top, black) map to exons after the breakpoint. Prefusion ETS RPKMs (bottom, black) are derived from alleles before the EWS -ETS breakpoint. Postfusion ETS RPKMs (red) are derived from exons after the breakpoint (reads from the rearranged and wild-type alleles cannot be distinguished). 
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by the Student t test; Fig. 5C ). We then applied ssGSEA after ranking the genes by their weighted contribution to PC1 and found that cell lines were enriched for gene sets associated with cell proliferation and metabolism, whereas tumors were enriched for gene sets associated with the immune system or signaling from the extracellular matrix ( Fig. 5D and Supplementary Table S17 ). In summary, these data suggest that although Ewing sarcoma cell lines possess the spectrum of recurrent molecular events observed in EWS-ETS-positive primary tumors, they may be more representative of high-risk disease because aberrancies associated with aggressive disease (e.g., TP53 mutations and CDKN2A deletions) occur at a higher frequency in the cell lines. Moreover, the transcriptional analysis suggests, not surprisingly, that there is an interaction of the primary tumors with the microenvironment, including infi ltration with immune cells, and that there are differences in growth properties between cell lines and primary Ewing sarcoma tumors . However, additional differences in transcription between the two were not identifi ed in our analysis, supporting the notion that other aspects of cell line transcriptional programming may more faithfully model tumor biology.
Clonal Evolution and Tumor Heterogeneity
For 2 patients, we performed WES on tumor DNA from both a primary tumor at diagnosis and a metastatic tumor at relapse ( Supplementary Fig. S7A and Supplementary with tumor samples (black). STAG2 loss refers to absence of protein expression by Western blot analysis or IHC. There was a statistically signifi cant increase in the percentage of cell lines with STAG2 mutation ( P = 0.016), STAG2 loss ( P = 0.0006), TP53 mutations ( P < 0.0001), CDKN2A loss ( P = 0.028), and chromosome 1q gain ( P = 0.011) compared with tumor samples by Fisher exact test. *, P < 0.05; ***, P < 0.001; ****, P < 0.0001. B, projection on the fi rst two components of a principal component analysis applied to RNASeq data from Ewing sarcoma tumors and cell lines. Principal components are ordered on the basis of the percentage of explained variance in the data. Black dots indicate tumor samples and red indicate cell lines. Cell lines and tumors separate into distinct clusters. C, plot of the normalized P value (by −log 10 ) of Student t tests comparing the principal component scores for tumors versus cell lines. The red line indicates a P = 0.05. Only PC1 has a signifi cant P value. D, plot of FDR q value (normalized by −log 10 ) versus normalized enrichment score (NES) of ssGSEA applied to genes (ranked by PC1-weight) to identify Kyoto Encyclopedia of Genes and Genomes (KEGG) canonical pathways enriched by differences in Ewing sarcoma tumors versus cell lines. A negative NES indicates a pathway enriched in tumors and a positive NES indicates a pathway enriched in cell lines. Black dots indicate signifi cant pathways (FDR q value < 0.05) associated with environmental interactions with the extracellular membrane, transmembrane signaling, and the immune system. Red dots indicate signifi cant pathways associated with cellular proliferation including cell division, growth, and metabolism. Signifi cantly enriched signatures are listed in Supplementary Table S17 . Tables S1D and S18). To explore clonal evolution, we estimated the cancer cell fraction (CCF; fraction of tumor cells containing each SNV and indel) for mutations in each tumor ( 49 ) . For both patients, it was notable that there were mutations at diagnosis predicted to be clonal or near-clonal (by a CCF > 0.9) that were not identifi ed in the metastatic recurrent tumor samples, suggesting either that mutational heterogeneity in the diagnostic sample was not detectable by standard tissue sampling techniques and sequencing read depth or that metastasis occurred early in disease development, before the emergence of the dominant clone in the primary tumor ( Fig. 6A ) . As might be expected, a portion of subclonal 
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mutations at diagnosis became clonal at relapse, and recurrent metastatic tumors acquired new mutations. For two additional patients, we were unable to obtain diagnostic samples for sequencing but were able to sequence tumors from separate relapses ( Supplementary Fig. S7B and Supplementary Tables S1D and S18). In both cases, relapses were local to the site of the diagnostic tumor, but there was remarkably little overlap in the mutations identifi ed at the fi rst relapse (R1) compared with the subsequent relapse (R2). For patient SJDES007, we confi rmed that the same genomic EWS -FLI breakpoint identifi ed by WGS in R1 was also present in R2, suggesting that these were not independent occurrences of Ewing sarcoma in the same patient. These fi ndings indicate that tumor heterogeneity in the primary tumor infl uences the mutational profi le of tumors at relapse ( Fig. 6B ) .
One striking observation from patient SJDES007 was the fi nding that the TP53 and STAG2 mutations identifi ed in tumor R1 were not detected at R2. Instead, mutations at different sites were detected in both of these genes at R2. This convergent evolution is consistent with the fi nding that mutations in these genes may co-occur more often than expected by chance and suggests that they play an important role in relapse ( Fig. 6B and Supplementary Table S11A-S11D). Although copy-number loss in R2 could account for the loss of the TP53 mutation initially seen in R1, copy-number loss is unlikely to explain the presence of different STAG2 mutations in tumors R1 and R2 because the STAG2 gene is located on the X chromosome and this is a male patient ( Supplementary  Fig. S7B ). In fact, the absence of STAG2 expression in the diagnostic sample (determined by IHC staining of a formalinfi xed paraffi n-embedded sample; Supplementary Table S12) suggests that the tumor populations that gave rise to each relapse had diverged before diagnosis, further supporting the notion that tumor heterogeneity at diagnosis infl uences tumor evolution at relapse. Finally, sequencing of tumors sampled at R1 and R2 from patient SJDES014, an infant with multiply relapsed chest wall Ewing sarcoma, demonstrated that the EWS -FLI rearrangement was the only somatic mutation in common to both relapses ( Fig. 6B and Supplementary  Tables S2B, S4C , and S18). Although analysis of this patient's normal exome did not reveal a mutation associated with a known cancer predisposition, the patient's unusually young age at diagnosis and the absence of other clonal, tumorinitiating events leads us to speculate that germline variants or lineage-specifi c epigenetic changes may play an important role in Ewing sarcoma oncogenesis for some patients.
DISCUSSION
One ongoing debate in the pediatric oncology community has focused on the utility of clinical-grade deep sequencing of pediatric tumors to enable molecularly informed therapy, matching genetic lesions with targeted drugs. In this regard, our study reveals that Ewing sarcoma genomes are among the most simple reported to date and demonstrates a marked paucity of mutations in immediately targetable pathways, such as mutations in the MAPK or PI3K-AKT-mTOR pathways. In the case of MAPK pathway mutations, a similar observation was made in prostate cancer in which mutations in the MAPK pathway were rare and observed only in ETS fusion-negative tumors ( 43 ) . Indeed, it has been suggested that oncogenic ETS proteins can replace the need for MAPK pathway mutations by the upregulation of a MAPK transcriptional program ( 50 ) . At relapse, the frequency of genetic aberrancies is signifi cantly higher, although the paucity of targetable lesions remains a challenge. This does raise the point, however, that diagnostic and relapsed tumors are quite different, supporting the notion that relapsed tissue warrants biopsy and genomic characterization for optimal precisionbased therapy in the future.
On the one hand, the simplicity of the Ewing sarcoma genome is disquieting in that there is not an immediately translatable intervention. In addition, in the two cases with paired relapse samples from the same patient, only the minority of mutations were present in both relapses. These results, however, do speak to the critical importance of understanding and either directly targeting the EWS -ETS fusion event in this disease or identifying synthetic lethal vulnerabilities in the presence of these fusion proteins. Toward this end, by integrating multiple genomic approaches, we addressed several previously outstanding questions regarding the EWS -ETS fusions in Ewing sarcoma tumors. First, in Ewing sarcoma, the reciprocal fusion, ETS -EWS , is generally not expressed and thus unlikely to be relevant to disease pathogenesis. This is in contrast to other fusions, such as PML -RARA in acute promyelocytic leukemia, in which the reciprocal fusion is thought to be critical to leukemogenesis ( 51 ) . Second, although wild-type EWS is highly expressed in Ewing sarcoma tumors, both wild-type FLI and wild-type ERG are poorly expressed. Third, our data highlight the need to better understand the role of nonrearranged ETS genes in Ewing sarcoma even beyond the expressed EWS-ETS fusion proteins.
One of the most striking recurrent events found in our sequencing effort was mutations or rearrangements of the STAG2 gene. In further support of a functional relevance of STAG2 to Ewing sarcoma is the fi nding of unique STAG2 mutations at different relapses in 1 patient. Moreover, the co-occurrence of these mutations with unique mutations in TP53 at each relapse supports a likely functional interaction of these two events in promoting disease recurrence. Indeed, co-occurrence of STAG2 and TP53 mutations was observed more often than expected by chance in Ewing sarcoma tumors. All frameshift and nonsense mutations in STAG2 resulted in the loss of protein expression in Ewing sarcoma tumors with suffi cient tissue for evaluation by IHC. Moreover, we observed additional samples with loss of STAG2 expression despite normal coding sequences. STAG2 is a member of the cohesin complex, a multimeric complex consisting of at least four core proteins: a heterodimer of SMC1 and SMC3 forming a hinged ring-like structure and two "clasp" proteins, STAG and RAD21 ( 52, 53 ) . Although mutations in multiple members of the cohesin complex have been reported in cancer, in this collection of Ewing sarcoma tumors, we observed recurrent mutations only in STAG2 , consistent with recent reports ( 4 , 16 , 54, 55 ) . The cohesin complex is known to play a role in the regulation of sister chromatid exchange during mitosis and meiosis, and in some reports, mutations in STAG2 are associated with aneuploidy ( 15 , 36 ) . In Ewing sarcoma tumors, however, there was no difference in tumor ploidy
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on December 22, 2017. © 2014 American Association for Cancer cancerdiscovery.aacrjournals.org Downloaded from among tumors expressing STAG2 or those with STAG2 loss. Furthermore, we have identifi ed a STAG2 mutation in one tumor sample with no copy-number alterations, suggesting that the loss of STAG2 expression likely contributes to disease pathogenesis or progression through other mechanisms. One alternative hypothesis is that mutations in STAG2 lead to altered chromatin architecture and transcription, a putative mechanism in the developmental disorders characterized by mutations in the cohesin complex, such as Cornelia de Lange Syndrome and Roberts Syndrome ( 53 , 56-59 ) . Moreover, despite a small sample size, it is notable that 88% of patients with STAG2 loss at diagnosis also had metastatic disease, in comparison to only 27% of patients with tumors expressing STAG2. Because of a lack of available follow-up data for the majority of patients whose tumors were included in this study, we were unable to defi nitively demonstrate that these patients had a worse outcome. Although metastatic disease is currently the most predictive marker of poor prognosis in Ewing sarcoma, this hypothesis will need verifi cation in a larger cohort. Thus, although loss-of-function mutations of STAG2 in Ewing sarcoma may portend a poor prognosis, it may also impart a new, targetable vulnerability for the development of alternative treatment strategies.
In this study, we also identifi ed rare, recurrent mutations in genes such as BCORL1 , MLL2 , and ERF , which did not reach statistical signifi cance in this dataset. Indeed, one of the shortcomings of comprehensive sequencing efforts for rare pediatric tumors, such as this study, is the lack of adequate samples to power the discovery of rare events. Assuming a stable mutational frequency of 0.62 mutations per Mb, we would need to sequence more than 200 tumor/normal pairs to have 90% power to identify mutations present in 5% of patients and approximately 500 samples to detect signifi cant events in 3% of patients ( 19 ) . With an incidence of approximately 250 cases in the United States per year, such an analysis will require a large multi-institutional effort or meta-analysis as data from other Ewing sarcoma sequencing projects become available. However, we present here a novel approach to utilizing tumors acquired from pathologic discards that do not have paired normal tissue. Although we expect to see an increase in false positives using this approach, this analysis increased our confi dence that we were not "missing" signifi cantly mutated, well-validated cancerassociated genes expected to occur in 15% or more of patients with Ewing sarcoma. It is yet to be seen whether this method will be as informative for other cancer types, particularly those with a much higher rate of somatic mutations. A second shortcoming of our study is the lack of deep clinical information for many of the samples. Prospective studies to defi nitively address the relevance of STAG2 aberrancy on long-term survival, for example, will be of future interest.
In summary, we report a massively parallel sequencing analysis of ETS -rearranged Ewing sarcoma tumors and reveal remarkably quiet genomes at the time of diagnosis. We note nearly a 3-fold increase in the mutation rate of tumors posttreatment, underscoring the notion that relapsed disease is genetically different from disease at diagnosis and lending support to the debate about re-biopsy of pediatric solid tumors at time of relapse. These studies emphasize the importance of tackling the EWS -ETS fusion as a drug target and also shed light on cohesin defects as another potential vulnerability in this disease.
METHODS

Samples
Tumor tissue and matched blood from patients with Ewing sarcoma were collected with informed consent under a Hospital Sant Joan de Déu (Barcelona, Spain), Institutional Review Board (IRB)-approved protocol . Additional tumor tissue samples were collected on an IRB-approved tissue discard protocol from Boston Children's Hospital (Boston, MA) and acquired through the Cooperative Human Tissue Network, Southern Division (Birmingham, AL). Protocols were reviewed and approved by the Broad Institute's (Cambridge, MA) IRB. DNA and RNA were extracted from tumors and cell lines using standard techniques.
Massively Parallel Sequencing
Whole-exome sequencing Library construction followed procedures as previously reported ( 60 ) . Barcoded exon capture libraries were pooled into batches of 96 samples for sequencing.
Whole-genome sequencing Creation of adaptor-ligated barcoded libraries was performed as for hybrid capture, except that DNA was sheared to a larger fragment size (adaptor-ligated fragment; range, 340-510 bp). To minimize molecular duplication and facilitate deep and diverse sequence coverage, two libraries were prepared from each sample.
Transcriptome sequencing RNA for each sample was converted into a library of template molecules for sequencing according to the protocol for the Illumina TruSeq unstranded RNA Sample Protocol ( 61 ) . All libraries were sequenced on the Illumina HiSeq 2000 instrument set to generate 76-bp paired-end reads for WES and RNASeq and 101-bp paired-end reads for WGS.
Genotyping arrays Tumor-normal matched samples were processed and hybridized to Affymetrix SNP 6.0 arrays for genotyping and copy-number analysis ( 62 ) .
Contamination estimates SNP fi ngerprinting was used to crosscheck each sequenced lane from a tumor-normal pair against all other lanes from that pair and to ensure matching between WES, WGS, SNP array, and RNASeq. Cross-contamination was estimated by using ContEst ( 63 ) . All samples were found to have less than 4% contamination.
Sequencing Analysis
DNA sequence alignment and variant detection To prepare read alignments for analysis, we processed all sequence data through the Broad Institute's data-processing pipeline, "Picard." For each sample, this pipeline combines data from multiple libraries and fl ow cell runs into a single BAM fi le. This fi le contains reads aligned to the human genome with quality scores recalibrated using the TableRecalibration tool from the Genome Analysis Toolkit (GATK; ref. 64 ) . Reads were aligned to the Human Genome Reference Consortium build 37 (GRCh37) using the Burrows-Wheeler Aligner. All BAM fi les were deposited in the database of Genotypes and Phenotypes (dbGaP) upon publication. Variant detection and analysis of the BAM fi les were performed using the Broad Institute's Cancer Genome Analysis infrastructure program "Firehose." Firehose facilitates comparison of BAM fi les from matched tumor-normal pairs and coordinates execution of specifi c modules including quality control, local realignment, mutation calling, small insertion and deletion identifi cation, rearrangement
Research. OncotatorPipeline v81) . We manually reviewed all somatic mutations and indels identifi ed in the 26 tumor-normal pairs by the automated pipeline using the Integrated Genomic Viewer (IGV; ref. 67 ) . Manual review removed approximately 20% of the somatic mutations from subsequent analysis, consistent with a very low false-positive rate (∼0.1/ Mb). Genomic rearrangements were detected from WGS and WES data using dRanger (Firehose dRanger v146) or manual review using IGV. Somatic copy-number variants were detected from SNP-array data using the Broad Institute's copy-number pipeline and from WES data using CapSeg (Firehose CapSegModule v77), which uses read depth in the exome to estimate somatic copy-number changes across the genome. SNP-array data were analyzed using the tool ABSOLUTE to infer the tumor purity and ploidy ( 49 , 68 ) .
Germline fi ltering for tumor-only and cell line samples We devised a fi ltering approach to reduce the nonsomatic component of mutations detected in tumor samples and cell lines without matched normal samples. The fi lter removed recurring germline mutations with population minor allele frequencies exceeding 0.5% and removed any candidate mutation occurring at sites of recurring artifacts identifi ed in more than 15% of a panel of 2,913 normal exomes. The processing for tumor-only and cell line data consisted of three steps.
The fraction of the 2,913 normal samples in each of the eight categories was calculated for each candidate mutation site. Candidate variants at loci that did not meet the following criteria were removed from subsequent analysis: Although approximately 150 rare germline variants per tumor sample pass this fi lter, we found that the nonsomatic:somatic ratio of mutations was reduced to approximately 12:1 with this method (based on the comparison of fi ltering of 26 tumors with and without pairing of normal samples), which is suffi cient for MutSig 2CV to identify signifi cantly recurring mutations above the background germline mutation rate ( 19 ) . Following the "panel of normal" fi lter, SNVs were also subjected to "oxo-G" fi ltering to remove C>A artifact from library preparation-associated oxidative damage ( 70 ) .
Determining DNA somatic variant signifi cance GISTIC2.0 (Firehose Gistic2_Pipeline v99) was used to identify signifi cantly recurring SCNAs from both SNP-array and WES data ( 33 ) . Identifi cation of gene mutations most likely to be driving tumorigenesis ( signifi cantly mutated genes) was performed by the MutSig 2CV algorithm ( 19 ) .
Estimating CCF Tumor purity and ploidy values were estimated using the ABSOLUTE Toolkit ( 68 ) based on SCNAs and SNV allele fractions. In samples without suffi cient aneuploidy for ABSOLUTE to converge on a solution, a custom MATLAB script estimated purity based on evidence from allele fraction distribution of mutations that were consistent with clonal heterozygous somatic SNVs. The CCF of each mutation was then estimated by ABSOLUTE or by the custom MATLAB script using purity and ploidy estimates ( 49 ) .
Transcriptome sequencing alignment and analysis The PRADA pipeline was used for alignment of RNA sequenced reads (Firehose BWATrancriptome v32) to a reference genome consisting of GRCh37 and the human transcriptome. Mutations detected from the WES and WGS were compared with RNASeq data from the same samples to estimate the mutation validation rate (Supplementary Fig. S2 ; Firehose CrossvalidateMutations v15; ref. 66 ) . RNA fusions were identifi ed from the PRADA pipeline (Firehose RNAFusion v19) based on reads containing mates mapping to two different coding regions. Exon-level transcript expression from RNASeq data was evaluated using RNA-SeQC (Firehose RNASeqMetrics v35; ref. 71 ) . Reads were then converted to gene-level expression by determining the reads mapped to the genome per kilobase per million mapped reads (RPKM) for each gene ( 72 ) . We also calculated gene-fragment RPKMs for the EWS , FLI , and ERG genes involved in EWS -ETS translocations. RPKM calculations for prefusion exon regions and for postfusion exon regions were performed separately for EWS , FLI , and ERG genes in each tumor sample.
Cell Culture
Ewing sarcoma cell lines were provided by the laboratory of Dr. Todd Golub (Broad Institute) except for the EWS502 and EWS834 cells, both of which were a gift from Dr. Jonathan Fletcher (Brigham and Women's Hospital, Boston, MA) and cultured as previously described ( 32 ) . CHLA-258 cells were grown in Iscove's Modifi ed Dulbecco's Medium (Invitrogen) with 20% heat-inactivated FBS (Gemini Bio-Products) and supplemented with 10 mg/L insulin, 5.5 mg/L transferrin, and 6.7 μg/L sodium selenite (ITS; Thermo Fisher Scientifi c IST) and 0.7 mmol/L L -glutamine (Thermo Fisher Scientifi c). Cell lines were authenticated with WES and RNASeq as described in the article .
Please see the Supplementary Data for additional methods.
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